Source: European Medicines Agency (EU) Revision Year: 2021 Publisher: Shionogi B.V., Kingsfordweg 151, 1043GR, Amsterdam, The Netherlands
Mulpleo 3 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Light red, 7.0 mm round film-coated tablets debossed with the Shionogi trademark above the identifier code “551” on one side and debossed on the other side with the strength “3”. |
Each film-coated tablet contains 3 mg of lusutrombopag.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Lusutrombopag |
Lusutrombopag is an orally active TPO receptor agonist. Lusutrombopag acts on the haematopoietic stem cells and on the transmembrane domain of human TPO receptors expressed in megakaryocytes, to stimulate the megakaryocyte to proliferate and differentiate via the similar signal transduction pathway for up-regulating production used by endogenous TPO, thus leading to thrombocytopoiesis. |
| List of Excipients |
|---|
|
Tablet core: Mannitol Film-coating: Hypromellose |
OPA/Aluminium foil/PVC film blister with push through aluminium lidding foil, packed in a cardboard box. Each box contains 7 film-coated tablets.
Shionogi B.V., Kingsfordweg 151, 1043GR, Amsterdam, The Netherlands
EU/1/18/1348
02/2019
| Drug | Countries | |
|---|---|---|
| MULPLEO | Austria, Estonia, Spain, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
